Methylpromazine

CHEMBL829 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

298.4 g/mol

LogP

4.7

Phase

4

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

الوزن الجزيئي

298,4000 g/mol

LogP

4,70

TPSA

31,80 Å²

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(CN(C)C)CN1c2ccccc2Sc2ccccc21

InChI

InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

Molecular Formula

C18H22N2S

HBD / HBA

- / 3

الروابط القابلة للدوران

4

الذرات الثقيلة

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Methylpromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL829. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5574. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Methylpromazine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C18H22N2S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.